These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30775846)

  • 21. Maximizing the Benefits of HIV Preexposure Prophylaxis.
    Buchbinder SP
    Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Referral Linkage to Preexposure Prophylaxis Care and Persistence on Preexposure Prophylaxis in an Integrated Health Care System.
    Bruxvoort KJ; Schumacher CM; Towner W; Jones J; Contreras R; Ling Grant D; Hechter RC
    J Acquir Immune Defic Syndr; 2021 Jul; 87(3):918-927. PubMed ID: 33633035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV PrEP access and affordability: a multidisciplinary specialty pharmacy model.
    Whelchel K; Zuckerman AD; DeClercq J; Choi L; Rashid S; Kelly SG
    J Am Pharm Assoc (2003); 2022; 62(3):853-858. PubMed ID: 34916170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012-2017.
    Huang YA; Tao G; Smith DK; Hoover KW
    Clin Infect Dis; 2021 Feb; 72(3):379-385. PubMed ID: 33527117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam.
    Hoornenborg E; Achterbergh RC; van der Loeff MFS; Davidovich U; van der Helm JJ; Hogewoning A; van Duijnhoven YT; Sonder GJ; de Vries HJ; Prins M;
    J Int AIDS Soc; 2018 Mar; 21(3):e25105. PubMed ID: 29603900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial.
    Haberer JE; Bukusi EA; Mugo NR; Pyra M; Kiptinness C; Oware K; Garrison LE; Thomas KK; Musinguzi N; Morrison S; Anderson PL; Ngure K; Baeten JM;
    Lancet HIV; 2021 Mar; 8(3):e130-e137. PubMed ID: 33662265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A taxonomy of pragmatic measures of HIV preexposure prophylaxis use.
    Pyra M; Rusie L; Castro M; Keglovitz Baker K; McNulty M; Bohm N; Prokurat A; Schneider J
    AIDS; 2020 Nov; 34(13):1951-1957. PubMed ID: 33009011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brief Report: Transgender Women and Preexposure Prophylaxis Care: High Preexposure Prophylaxis Adherence in a Real-World Health Care Setting in New York City.
    Starbuck L; Golub SA; Klein A; Harris AB; Guerra A; Rincon C; Radix AE
    J Acquir Immune Defic Syndr; 2022 May; 90(1):15-19. PubMed ID: 35013087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting.
    Montgomery MC; Oldenburg CE; Nunn AS; Mena L; Anderson P; Liegler T; Mayer KH; Patel R; Almonte A; Chan PA
    PLoS One; 2016; 11(6):e0157742. PubMed ID: 27333000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to Daily Oral TDF/FTC for PrEP in Community Health Center Populations: The Sustainable Health Center Implementation PrEP Pilot (SHIPP) Study.
    Smith DK; Rawlings MK; Glick N; Mena L; Coleman M; Houlberg M; McCallister S; Wiener J
    AIDS Behav; 2022 Feb; 26(2):350-360. PubMed ID: 34347198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
    Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
    AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Out-of-pocket costs and HIV pre-exposure prophylaxis persistence in a US multicity demonstration project.
    Furukawa NW; Schneider JA; Coleman ME; Wiener JB; Shrestha RK; Smith DK
    Health Serv Res; 2020 Aug; 55(4):524-530. PubMed ID: 32196656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding PrEP Persistence: Provider and Patient Perspectives.
    Laborde ND; Kinley PM; Spinelli M; Vittinghoff E; Whitacre R; Scott HM; Buchbinder SP
    AIDS Behav; 2020 Sep; 24(9):2509-2519. PubMed ID: 32048078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
    JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study on Pre-Exposure Prophylaxis Regimens among Men Who Have Sex with Men: A Prospective Cohort Study.
    Wu D; Tao H; Dai J; Liang H; Huang A; Zhong X
    Int J Environ Res Public Health; 2019 Dec; 16(24):. PubMed ID: 31818006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.